Literature DB >> 12463600

Using related donors other than genotypically HLA-matched siblings in allogeneic hematopoietic stem cell transplantation for hematologic disease: a single institution experience in Japan.

Akira Tomonari1, Tohru Iseki, Jun Ooi, Satoshi Takahashi, Koji Ishii, Tsutomu Takahashi, Motohiro Shindo, Fumitaka Nagamura, Kaoru Uchimaru, Hitomi Nagayama, Naoki Shirafuji, Arinobu Tojo, Kenzaburo Tani, Shigetaka Asano.   

Abstract

Thirty patients with hematologic diseases received allogeneic hematopoietic stem cell transplants (HSCT) from related donors other than genotypically HLA-matched siblings. Their outcomes were compared with those of 102 patients who had received HSCT from genotypically HLA-matched siblings. All donors in the study group were HLA-haploidentical relatives, The degree of HLA mismatches in unshared haplotype was 0-locus (n = 6), 1-locus (n = 20), and 2-locus (n = 4). All patients in the study group achieved successful engraftment at a median of 17 days (range, 10-35 days). Grade II-IV and ITI-IV acute graft-versus-host disease (GVHD) occurred in 16 (53%) and 9 (30%) patients, respectively, in the study group, rates that were significantly higher than those of the control group, which were 33 (33%) and 12 (12%) patients, respectively (P = .034 and .022, respectively). The frequency of chronic GVHD was 85% (22 out of 26 evaluable patients) in the study group, a rate that was also significantly higher than that of the control group with 57% (52 of 91 patients) (P = .0078). The estimated probability of disease-free survival (DFS) for the study group was 56% at 5 years. When the 2 groups were compared according to the risk of disease, the probabilities of DFS at 5 years for patients with low risk in the study and for control groups were 100% and 84%, respectively, and those for patients with high risk were 43% and 42%, respectively. These results showed that the DFS for patients with both low and high risks in the study group was comparable to that of the control group. In conclusion, despite higher probabilities of acute and chronic GVHD, unmanipulated allogeneic HSCT from related donors other than genotypically HLA-matched siblings was considered to be a reasonable alternative for patients without genotypically HLA-matched sibling donors.

Entities:  

Mesh:

Year:  2002        PMID: 12463600     DOI: 10.1007/bf02982696

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  17 in total

1.  Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors.

Authors:  M J Laughlin; J Barker; B Bambach; O N Koc; D A Rizzieri; J E Wagner; S L Gerson; H M Lazarus; M Cairo; C E Stevens; P Rubinstein; J Kurtzberg
Journal:  N Engl J Med       Date:  2001-06-14       Impact factor: 91.245

2.  Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma.

Authors:  C Anasetti; P G Beatty; R Storb; P J Martin; M Mori; J E Sanders; E D Thomas; J A Hansen
Journal:  Hum Immunol       Date:  1990-10       Impact factor: 2.850

3.  Use of partially mismatched related donors extends access to allogeneic marrow transplant.

Authors:  P J Henslee-Downey; S H Abhyankar; R S Parrish; A R Pati; K T Godder; W J Neglia; K S Goon-Johnson; S S Geier; C G Lee; A P Gee
Journal:  Blood       Date:  1997-05-15       Impact factor: 22.113

4.  Unrelated cord blood transplantation for adult patients with myelodysplastic syndrome-related secondary acute myeloid leukaemia.

Authors:  J Ooi; T Iseki; H Nagayama; A Tomonari; K Ito; N Shirafuji; A Tojo; K Tani; S Asano
Journal:  Br J Haematol       Date:  2001-09       Impact factor: 6.998

5.  [Bone marrow transplantation from donors other than HLA matched siblings for hematological malignancies. Nagoya Bone Marrow Transplantation Group and Tokai Marrow Donor Bank].

Authors:  K Matsumoto; K Horibe; Y Akatsuka; S Minami; T Matsuyama; N Hirabayashi; M Tanimoto; H Yamada; R Sobue; Y Morishima
Journal:  Rinsho Ketsueki       Date:  1994-08

6.  Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program.

Authors:  T Sasazuki; T Juji; Y Morishima; N Kinukawa; H Kashiwabara; H Inoko; T Yoshida; A Kimura; T Akaza; N Kamikawaji; Y Kodera; F Takaku
Journal:  N Engl J Med       Date:  1998-10-22       Impact factor: 91.245

7.  Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion.

Authors:  R C Ash; M M Horowitz; R P Gale; D W van Bekkum; J T Casper; E C Gordon-Smith; P J Henslee; H J Kolb; B Lowenberg; T Masaoka
Journal:  Bone Marrow Transplant       Date:  1991-06       Impact factor: 5.483

8.  Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia.

Authors:  S Takahashi; S I Okamoto; N Shirafuji; K Ikebuchi; K Tani; M Shimane; T Matsudaira; S Irie; T Tsuruta; E Matsuishi
Journal:  Bone Marrow Transplant       Date:  1994-03       Impact factor: 5.483

9.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

10.  Bone marrow transplantation from partially HLA-matched related donors in adults with leukaemia: the experience at the University Hospital of Essen, Germany.

Authors:  H Ottinger; D Beelen; H Sayer; U W Schaefer; H Grosse-Wilde
Journal:  Br J Haematol       Date:  1996-03       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.